Tenpoint Therapeutics
Latest round
- Series B
Last raised
- Jan 2026
Total raised
- $155M
Investors
- 13
About Tenpoint Therapeutics
a. Tenpoint Therapeutics operates as a biotech company that is developing vision-restoring engineered cell-based therapeutics and in vivo reprogramming to address degenerative ocular diseases. As of July 2023, Eddy Anglade is the CEO of the company. The company is developing engineered cell-based therapeutics and in vivo reprogramming to reverse vision loss caused by the deterioration of functional tissue. Tenpoint Therapeutics also develops a regenerative medicine platform that helps replace cells destroyed by both age-related and inherited ocular diseases.
Who invested in Tenpoint Therapeutics
13 investors across 2 rounds
See all investors in Tenpoint Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Tenpoint Therapeutics
Who invested in Tenpoint Therapeutics?
Tenpoint Therapeutics has 13 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Tenpoint Therapeutics raised?
Tenpoint Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Tenpoint Therapeutics last raise money?
Tenpoint Therapeutics's most recent round on record is a Series B, in Jan 2026.
What does Tenpoint Therapeutics do?
Tenpoint Therapeutics is a biotechnology company.
Where is Tenpoint Therapeutics headquartered?
Tenpoint Therapeutics is headquartered in London, UK.
Which VCs invest in companies like Tenpoint Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Tenpoint Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Tenpoint Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.